Mark J. Macielag
ScholarGPS® ID: 71837580292485
Affiliation History
Discipline
Chemistry
Top Specialties
Medicinal Chemistry | Antibacterial Activity | Antimicrobial | Chemical Synthesis | Bacteria | Antibiotic | Erythromycin | Chemotherapy | Receptor Modulator | Diabetes | Opioid | Opioid Receptor | Receptor Antagonist | Antibody | Carboxylic Acid
Metrics Summary
Publication Count
174
Predicted Citations
4,728
Predicted h-index
35
Ranking
Publications and Citation History
Publications based on Top Specialties
Types of Publication
- Publications
- Books
- Patents
- NIH/NSF
Add
Delete
|
---|
Design, synthesis and preclinical evaluation of bio-conjugated amylinomimetic peptides as long-acting amylin receptor agonists (journal article) European Journal of Medicinal Chemistry, volume 236 (2022). |
Discovery and Optimization of 7-Alkylidenyltetrahydroindazole-Based Acylsulfonamide EP3 Antagonists (journal article) ACS Medicinal Chemistry Letters, volume 13, issue 1, pages 111-117 (2022). |
Erratum to “Optimization of physicochemical properties of pyridone-based EP3 receptor antagonists” [Bioorg. Med. Chem. Lett. 47 (2021) 128172] (journal article) Bioorganic & Medicinal Chemistry Letters, volume 47 (2021). |
Optimization of physicochemical properties of pyridone-based EP3 receptor antagonists (journal article) Bioorganic & Medicinal Chemistry Letters, volume 47 (2021). |
Discovery of a novel series of guanidinebenzoates as gut-restricted enteropeptidase and trypsin dual inhibitors for the treatment of metabolic syndrome (journal article) Bioorganic & Medicinal Chemistry Letters, volume 40 (2021). |
Discovery of a Novel Series of Pyridone-Based EP3 Antagonists for the Treatment of Type 2 Diabetes (journal article) ACS Medicinal Chemistry Letters, volume 12, issue 3, pages 451-458 (2021). |
Discovery of PEGylated 6-Benzhydryl-4-amino-quinazolines as Peripherally Restricted CB1 R Inverse Agonists (journal article) ACS Medicinal Chemistry Letters, volume 11, issue 12, pages 2504-2509 (2020). |
Expert Opinion on Therapeutic Patents, volume 30, issue 10, pages 729-742 (2020). |
The discovery of azetidine-piperazine di-amides as potent, selective and reversible monoacylglycerol lipase (MAGL) inhibitors (journal article) Bioorganic & Medicinal Chemistry Letters, volume 30, issue 14, pages 127243- (2020). |
The discovery of diazetidinyl diamides as potent and reversible inhibitors of monoacylglycerol lipase (MAGL) (journal article) Bioorganic & Medicinal Chemistry Letters, volume 30, issue 12, pages 127198- (2020). |
Patent Number: 10640544 (2020) |
Patent Number: 10590083 (2020) |
Journal of Pharmacology and Experimental Therapeutics, volume 372, issue 3, pages 339-353 (2020). |
Patent Number: 10399944 (2019) |
Patent Number: 10336701 (2019) |
A Long-Acting PYY3–36 Analog Mediates Robust Anorectic Efficacy with Minimal Emesis in Nonhuman Primates (journal article) Cell Metabolism, volume 29, issue 4, pages 837-843.e5 (2019). |
Injectable Diabetes Treatments Targeting Glucose Regulation and Satiety Pathways (book chapter) In 2018 Medicinal Chemistry Reviews Medicinal Chemistry Division of the American Chemical Society (2018) |